Enliven Therapeutics, Inc. (ELVN) shareholders
Close on Nov 18, 2026Market cap $3.29BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Polar Capital Holdings Plc Joint filing with Polar Capital LLP (8.47%), Polar Capital Funds PLC - Biotechnology Fund (8.47%) | 59,800,406 | 8.47% | 13G (passive) amendment | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 10,713,540 | 15.00% | 13G (passive) amendment | Jun 30, 2026 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vii LLC (9.20%) | 6,774,507 | 9.50% | 13D (active) amendment | Jun 22, 2026 |
| BlackRock, Inc. | 5,206,581 | 7.10% | 13G (passive) amendment | Sep 30, 2026 |
| Polar Capital LLP Joint filing with Polar Capital Holdings Plc (8.46%), Polar Capital Funds PLC - Biotechnology Fund (8.46%) | 5,056,807 | 8.46% | 13G (passive) amendment | Mar 31, 2026 |
| Michael Kramarz Joint filing with Commodore Capital LP (7.70%), Commodore Capital Master LP (7.70%) and 1 more | 4,800,940 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (6.50%) | 3,830,000 | 6.50% | 13G (passive) | Dec 31, 2025 |
| Fairmount Funds Management LLC Joint filing with Fairmount Healthcare Fund II L.P. (6.30%), Peter Harwin (6.30%) and 1 more | 3,711,444 | 6.30% | 13G (passive) amendment | Jun 30, 2025 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (5.40%) | 3,250,000 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
| VHCP Management EG, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.40%), VHCP Co-Investment Holdings III, LLC (5.40%) and 4 more | 3,226,331 | 5.40% | 13G (passive) amendment | Sep 30, 2025 |
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (6.60%), Fairmount Healthcare Fund II L.P. (6.60%) and 1 more | 3,202,798 | 6.60% | 13G (passive) amendment | Dec 31, 2024 |
| Polar Capital Funds PLC - Biotechnology Fund Joint filing with Polar Capital Holdings Plc (5.17%), Polar Capital LLP (5.17%) | 2,536,881 | 5.17% | 13G (passive) | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 10,025,017 | 13.68% | $508.77M | +3,195,771 | 0.02% |
| Orbimed Advisors LLC | 6,776,632 | 9.25% | $343.91M | −1,182,906 | 6.37% |
| Polar Capital Holdings Plc | 6,430,636 | 8.78% | $326.35M | +1,364,703 | 0.77% |
| BlackRock, Inc. | 4,359,704 | 5.95% | $221.25M | +674,997 | 0.00% |
| Vestal Point Capital, LP | 4,000,000 | 5.46% | $203.00M | +750,000 | 4.74% |
| Commodore Capital LP | 3,275,000 | 4.47% | $166.21M | – | 9.90% |
| Price T Rowe Associates Inc /Md/ | 2,903,907 | 3.96% | $147.37M | +2,806,160 | 0.01% |
| Vanguard Capital Management LLC | 2,569,002 | 3.51% | $130.38M | +400,840 | 0.00% |
| Citadel Advisors LLC | 2,068,992 | 2.82% | $105.00M | +325,077 | 0.01% |
| Fairmount Funds Management LLC | 1,855,644 | 2.53% | $94.17M | – | 6.22% |
| Siren, L.L.C. | 1,774,411 | 2.42% | $90.05M | +1,028,185 | 1.82% |
| Bellevue Group AG | 1,490,000 | 2.03% | $75.62M | −830,867 | 1.59% |
| Geode Capital Management, LLC | 1,407,202 | 1.92% | $71.43M | +340,782 | 0.00% |
| First Light Asset Management, LLC | 1,360,750 | 1.86% | $69.06M | +1,158,883 | 4.20% |
| State Street Corp | 1,213,616 | 1.66% | $61.59M | +122,510 | 0.00% |
| Pictet Asset Management Holding SA | 1,161,784 | 1.59% | $58.96M | +232,240 | 0.06% |
| Adage Capital Partners Gp, L.L.C. | 1,083,313 | 1.48% | $54.98M | New | 0.08% |
| Novo Holdings A/S | 1,000,000 | 1.36% | $50.75M | −280,000 | 2.95% |
| First Turn Management, LLC | 954,360 | 1.30% | $48.43M | +330,521 | 5.18% |
| Samlyn Capital, LLC | 912,637 | 1.25% | $46.32M | New | 0.75% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 80M | 100.0% | 63 / 87 | 48 / 18 | 25M | 7M |
| Q1 2026 | 170 | 63M | 86.2% | 64 / 63 | 32 / 19 | 18M | 14M |
| Q4 2025 | 126 | 62M | 85.2% | 20 / 46 | 45 / 26 | 8M | 5M |
| Q3 2025 | 134 | 59M | 81.1% | 20 / 59 | 32 / 10 | 5M | 5M |
| Q2 2025 | 124 | 60M | 81.2% | 24 / 57 | 23 / 20 | 13M | 3M |
| Q1 2025 | 121 | 50M | 68.1% | 22 / 42 | 35 / 13 | 2M | 2M |
| Q4 2024 | 113 | 50M | 67.7% | 22 / 45 | 25 / 11 | 4M | 3M |
| Q3 2024 | 102 | 48M | 65.1% | 20 / 41 | 23 / 10 | 6M | 4M |
| Q2 2024 | 93 | 49M | 66.8% | 32 / 36 | 15 / 12 | 8M | 4M |
| Q1 2024 | 74 | 45M | 60.9% | 16 / 26 | 21 / 3 | 7M | 2M |
| Q4 2023 | 62 | 39M | 53.4% | 8 / 24 | 12 / 7 | 2M | 2M |
| Q3 2023 | 61 | 39M | 53.3% | 6 / 22 | 22 / 8 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
207 funds held ELVN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ELVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,883,372 | 2.57% | $95.58M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,250,754 | 1.71% | $68.55M | 0.78% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,120,000 | 1.53% | $44.32M | 0.77% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,117,241 | 1.52% | $56.70M | 0.07% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 807,329 | 1.10% | $40.97M | 0.28% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 670,000 | 0.91% | $36.72M | 1.18% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 648,114 | 0.88% | $35.52M | 0.77% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 647,454 | 0.88% | $32.86M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 624,675 | 0.85% | $31.70M | 0.03% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 579,691 | 0.79% | $31.77M | 0.43% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 501,368 | 0.68% | $27.48M | 1.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 468,494 | 0.64% | $25.68M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 468,248 | 0.64% | $23.76M | 0.24% | Jun 30, 2026 |
| Small Cap Growth Fund | 427,901 | 0.58% | $23.45M | 0.42% | Jul 31, 2026 |
| Fidelity U.S. Equity Central Fund | 400,000 | 0.55% | $20.30M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard A. Fair | PRESIDENT AND CEO, Director | – | – | Dec 12, 2025 |
| Samuel Kintz | PRESIDENT AND CEO, Director | 890,392 | 1.22% | Nov 19, 2025 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | 38,000 | 0.05% | Oct 21, 2026 |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | 25,000 | 0.03% | Oct 21, 2026 |
| Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | 758,938 | 1.04% | Feb 17, 2026 |
| Anish Patel | CHIEF OPERATING OFFICER | 235,011 | 0.32% | Feb 17, 2026 |
| Lori Anne Kunkel | Director | 52,925 | 0.07% | Nov 3, 2026 |
| Kristine M. Ball | Director | – | – | Oct 16, 2026 |
| J. Scott Garland | Director | 0 | – | Oct 5, 2026 |
| Mika K. Derynck | Director | 87,373 | 0.12% | Aug 6, 2026 |
| Richard A. Heyman | Director | 146,320 | 0.20% | Feb 19, 2026 |
| Jake Bauer | Director | 87,372 | 0.12% | Feb 17, 2026 |
| Rahul D. Ballal | Director | 22,341 | 0.03% | Feb 17, 2026 |
| Rishi Gupta | Director | 7,663,349 | 10.46% | Feb 17, 2026 |
| Andrew John Phillips | Director | – | – | Feb 10, 2025 |
| Capital GP VII LLC OrbiMed | 10% owner | 7,663,349 | 10.46% | Jun 24, 2026 |
| Advisors Llc Orbimed | 10% owner | 219,405 | 0.30% | Jun 24, 2026 |
| Genesis GP LLC OrbiMed | 10% owner | 8,661,225 | 11.82% | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lori Anne Kunkel Director | Oct 30, 2026 | Option exercise | +7,300 | $18.30 | $133.59K | 52,925 |
| Lori Anne Kunkel Director | Oct 30, 2026 | Option exercise | +3,741 | $1.12 | $4.19K | 45,625 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Oct 19, 2026 | Sale(10b5-1 plan) | −6,018 | $38.48 | $231.55K | 38,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Oct 19, 2026 | Option exercise | +6,018 | $14.85 | $89.37K | 44,018 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Oct 19, 2026 | Sale(10b5-1 plan) | −5,000 | $38.47 | $192.34K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Oct 19, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| J. Scott Garland Director | Oct 1, 2026 | Sale | −13,000 | $46.67 | $606.72K | 0 |
| J. Scott Garland Director | Oct 1, 2026 | Option exercise | +13,000 | $15.47 | $201.11K | 13,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −240 | $51.48 | $12.36K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −2,916 | $50.03 | $145.89K | 27,084 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −1,844 | $50.71 | $93.51K | 25,240 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −289 | $51.49 | $14.88K | 38,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −2,194 | $50.72 | $111.28K | 38,289 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −3,535 | $50.03 | $176.86K | 40,483 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Option exercise | +3,982 | $14.85 | $59.13K | 44,018 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −1,100 | $59.35 | $65.29K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −3,900 | $58.37 | $227.64K | 26,100 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −1,388 | $59.35 | $82.38K | 40,036 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −4,630 | $58.35 | $270.16K | 41,424 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +87,373 | $2.48 | $216.69K | 87,373 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +27,567 | $25.28 | $696.89K | 114,940 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +23,364 | $14.85 | $346.96K | 138,304 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +20,491 | $22.47 | $460.43K | 158,795 |
| Mika K. Derynck Director | Aug 4, 2026 | Sale(10b5-1 plan) | −158,795 | $60.21 | $9.56M | 0 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −459 | $51.55 | $23.66K | 29,310 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −231 | $50.05 | $11.56K | 29,769 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −63 | $53.92 | $3.40K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,184 | $53.42 | $116.67K | 25,063 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,063 | $52.39 | $108.08K | 27,247 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,564 | $52.32 | $134.15K | 48,815 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −369 | $51.48 | $19.00K | 51,379 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −324 | $49.97 | $16.19K | 51,748 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Option exercise | +1,072 | $2.48 | $2.66K | 52,072 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,638 | $53.38 | $140.82K | 46,177 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −123 | $53.87 | $6.63K | 46,054 |
| Lori Anne Kunkel Director | Jul 6, 2026 | Sale(10b5-1 plan) | −4,111 | $49.98 | $205.47K | 47,773 |
| Lori Anne Kunkel Director | Jul 6, 2026 | Sale(10b5-1 plan) | −5,889 | $50.84 | $299.40K | 41,884 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −1,477 | $45.00 | $66.47K | 219,405 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −787,024 | $45.38 | $35.72M | 6,601,878 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −46,776 | $45.00 | $2.10M | 6,555,102 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −24,846 | $45.38 | $1.13M | 220,882 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,133 | $44.74 | $50.69K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −2,599 | $43.87 | $114.02K | 26,133 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,268 | $42.83 | $54.31K | 28,732 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,379 | $42.79 | $59.01K | 55,639 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −3,401 | $43.86 | $149.17K | 52,238 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,238 | $44.75 | $55.40K | 51,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Option exercise | +6,018 | $2.48 | $14.92K | 57,018 |
| Advisors Llc Orbimed 10% owner | Jun 15, 2026 | Sale | −272,322 | $45.02 | $12.26M | 7,388,902 |
| Advisors Llc Orbimed 10% owner | Jun 15, 2026 | Sale | −9,086 | $45.02 | $409.05K | 245,728 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,867 | $35.36 | $66.02K | 52,238 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −7,779 | $34.28 | $266.66K | 54,105 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −354 | $35.82 | $12.68K | 51,884 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Sale(10b5-1 plan) | −223 | $41.21 | $9.19K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Sale(10b5-1 plan) | −3,475 | $39.53 | $137.37K | 26,525 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Enliven Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 28,913 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Helen Louise Collins Director | Oct 19, 2026 | 15,000 | $559.80K | Oct 19, 2026 | Stock Options |
| Jeffrey Garland Director | Oct 1, 2026 | 13,000 | $606.72K | Oct 1, 2026 | Stock Option Exercise |
| Benjamin Hohl Officer | Sep 17, 2026 | 12,036 | $591.21K | Sep 17, 2026 | Long shares from previous exercised options |
| Richard A. Heyman resigned from BOD | Sep 4, 2026 | 38,000 | $2.25M | Sep 4, 2026 | Stock Options Exercise |
| Mika K. Derynck Director | Aug 4, 2026 | 158,795 | $9.22M | Aug 4, 2026 | Stock Options |
| Helen Louise Collins Officer | Jul 17, 2026 | 15,000 | $762.90K | Jul 17, 2026 | Stock Options |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Jun 22, 2026 | 26,323 | $1.21M | Jun 22, 2026 | Merger |
| OrbiMed Private Investments VII, LP Shareholder | Jun 22, 2026 | 833,800 | $38.32M | Jun 22, 2026 | Merger |
| The Biotech Growth Trust PLC Shareholder | Jun 22, 2026 | 31,132 | $1.43M | Jun 22, 2026 | Merger |
| Benjamin Hohl Officer | Jun 17, 2026 | 18,054 | $768.20K | Jun 17, 2026 | Stock Option Exercise |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Jun 15, 2026 | 9,086 | $384.88K | Jun 15, 2026 | Merger |
| OrbiMed Private Investments VII, LP Shareholder | Jun 15, 2026 | 272,322 | $11.54M | Jun 15, 2026 | Merger |
| The Biotech Growth Trust PLC Shareholder | Jun 15, 2026 | 10,243 | $433.89K | Jun 15, 2026 | Merger |
| Lori Anne Kunkel Board Member | Jun 5, 2026 | 20,000 | $709.80K | Jun 5, 2026 | Pre-IPO Shares |
| Helen Louise Collins Officer | May 18, 2026 | 15,000 | $620.10K | May 18, 2026 | Stock Options |
See a number that looks wrong?